Abbott Receives FDA 510(K) Clearance for the First Rapid Han
ABBOTT PARK, Ill., January 19, 2021 /3BL Media/ -- Abbott (NYSE: ABT) has received 510(k) clearance for the first rapid handheld traumatic brain injury (TBI) blood test, which will help clinicians assess individuals with suspected mild TBIs, including concussions. The test will run on Abbott's handheld i-STAT™ Alinity™ platform. Tests results are available within 15 minutes after plasma is placed in the test cartridge. TBIs, including concussions, are an alteration in brain function caused by an external force. This test measures specific proteins present in the blood after a TBI. A neg...
Source: 3blmedia.com